LLY

985.94

-1.8%↓

JNJ

228.38

+0.71%↑

ABBV

208.36

-0.98%↓

UNH

386.11

-1.92%↓

AZN

183.56

+1.07%↑

LLY

985.94

-1.8%↓

JNJ

228.38

+0.71%↑

ABBV

208.36

-0.98%↓

UNH

386.11

-1.92%↓

AZN

183.56

+1.07%↑

LLY

985.94

-1.8%↓

JNJ

228.38

+0.71%↑

ABBV

208.36

-0.98%↓

UNH

386.11

-1.92%↓

AZN

183.56

+1.07%↑

LLY

985.94

-1.8%↓

JNJ

228.38

+0.71%↑

ABBV

208.36

-0.98%↓

UNH

386.11

-1.92%↓

AZN

183.56

+1.07%↑

LLY

985.94

-1.8%↓

JNJ

228.38

+0.71%↑

ABBV

208.36

-0.98%↓

UNH

386.11

-1.92%↓

AZN

183.56

+1.07%↑

Strona główna・Stock List・ADMA Biologics Inc

ADMA Biologics Inc

Open

SectorHealthcare

8.31 0.97

Buy Sell

Overview

Share price change

24h

Current

Min

8.23

Max

8.4

Key metrics
By Trading Economics
Income	-4.1M 45M
Sales	-25M 114M
P/E Sector Avg	11.588 51.415
EPS	0.17
Profit margin	39.59
Employees	640
EBITDA	-13M 52M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+186.22% upside

Dividends
By Dow Jones
Next Earnings	5 sie 2026

Market Stats
By TradingEconomics
Market Cap	-569M 1.8B
Previous open	7.34
Previous close	8.31

News Sentiment

By Acuity

44%

56%

115 / 345 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

N/A / 23.5406 Support & Resistance

ADMA Biologics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

17 maj 2026, 23:53 UTC

Acquisitions, Mergers, Takeovers

Prudential PLC to Buy Majority Stake in India Life Insurer for $389 Million

15 maj 2026, 22:47 UTC

Hot Stocks

Stocks to Watch: Macy's, Delta, UnitedHealth, NextNRG

15 maj 2026, 22:16 UTC

Acquisitions, Mergers, Takeovers

Canadian Tribunal Gives Keyera, Plains Until Late June to Rebut Bid to Undo Merger

15 maj 2026, 22:00 UTC

Major Market Movers

Delta Air Shares Rise as Berkshire Hathaway Discloses Stake

15 maj 2026, 18:09 UTC

Major Market Movers

Palo Alto Shares Head for Record-High Close, Analysts See Benefits to Identity Security Pivot

17 maj 2026, 23:50 UTC

Market Talk

Gold Consolidates; May be Weighed by Fed Rate-Hike Expectations -- Market Talk

17 maj 2026, 23:43 UTC

Market Talk

Global Equities Roundup: Market Talk

17 maj 2026, 23:43 UTC

Market Talk

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

17 maj 2026, 23:36 UTC

Market Talk

Oil Rises Amid Prospects of Prolonged Strait of Hormuz Closure -- Market Talk

17 maj 2026, 23:07 UTC

Acquisitions, Mergers, Takeovers

UOB: Transactions Part of Group's Capital Reallocation Strategy

17 maj 2026, 23:06 UTC

Acquisitions, Mergers, Takeovers

UOB: Share Sale Agreements Entered With Singland Properties

17 maj 2026, 23:05 UTC

Acquisitions, Mergers, Takeovers

UOB: Divestments' Aggregate Consideration of S$299M in Cash

17 maj 2026, 22:31 UTC

Acquisitions, Mergers, Takeovers

Prudential PLC to Fund Stake Acquisition via Internal Resources

17 maj 2026, 22:31 UTC

Acquisitions, Mergers, Takeovers

Prudential PLC to Acquire Stake for $389 Million

17 maj 2026, 22:30 UTC

Acquisitions, Mergers, Takeovers

Prudential PLC to Acquire 75% Stake in Bharti Life Insurance

16 maj 2026, 16:27 UTC

Acquisitions, Mergers, Takeovers

NextEra Is In Talks to Buy Dominion, Report Says. What a Deal Could Mean. -- Barrons.com

16 maj 2026, 15:26 UTC

Acquisitions, Mergers, Takeovers

NextEra Energy Near Deal for Rival Utility Dominion -- WSJ

16 maj 2026, 08:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15 maj 2026, 22:17 UTC

Acquisitions, Mergers, Takeovers

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 maj 2026, 21:59 UTC

Acquisitions, Mergers, Takeovers

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying. -- Barrons.com

15 maj 2026, 21:50 UTC

Acquisitions, Mergers, Takeovers

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 maj 2026, 21:30 UTC

Acquisitions, Mergers, Takeovers

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 4th Update

15 maj 2026, 21:16 UTC

Market Talk

Canada Oil Producers Expect Govt Cash Before Building Pathways Project -- Market Talk

15 maj 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15 maj 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

15 maj 2026, 20:19 UTC

Hot Stocks

Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ

15 maj 2026, 19:41 UTC

Acquisitions, Mergers, Takeovers

SanDisk Stock Is Up 494% This Year. Insiders Are Cashing In on the AI-Fueled Surge. -- Barrons.com

15 maj 2026, 19:35 UTC

Market Talk

Oil Futures Settle Higher on Inventory Worries -- Market Talk

15 maj 2026, 19:33 UTC

Market Talk

U.S. Natural Gas Futures Rise as Weather Heats Up -- Market Talk

15 maj 2026, 18:35 UTC

Earnings

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

Peer Comparison

Price change

ADMA Biologics Inc Forecast

Price Target

By TipRanks

186.22% upside

12 Months Forecast

Average 23.67 USD 186.22%

High 30 USD

Low 20 USD

Based on 3 Wall Street analysts offering 12 month price targets forADMA Biologics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

3 ratings

Buy

Hold

Sell

Based on 3 analysts giving stock ratings to ADMA Biologics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

N/A / 23.5406Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

There is one bullish event.

Sentiment

By Acuity

115 / 345 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About ADMA Biologics Inc

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.